Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis
- PMID: 28692110
- DOI: 10.1160/TH17-02-0097
Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis
Abstract
Carboxypeptidase U (CPU, CPB2, TAFIa) is a basic carboxypeptidase that is able to attenuate fibrinolysis. The inactive precursor procarboxypeptidase U is converted to its active form by thrombin, the thrombin-thrombomodulin complex or plasmin. The aim of this study was to investigate and characterise the time course of CPU generation in healthy individuals. In plasma of 29 healthy volunteers, CPU generation was monitored during in vitro clot lysis. CPU activity was measured by means of an enzymatic assay that uses the specific substrate Bz-o-cyano-Phe-Arg. An algorithm was written to plot the CPU generation curve and calculate the parameters that define it. In all individuals, CPU generation was biphasic. Marked inter-individual differences were present and a reference range was determined. The endogenous CPU generation potential is the composite effect of multiple factors. With respect to the first CPU activity peak characteristics, we found correlations with baseline proCPU concentration, proCPU Thr325Ile polymorphism, time to clot initiation and the clot lysis time. The second CPU peak related with baseline proCPU levels and with the maximum turbidity of the clot lysis profile. In conclusion, our method offers a technique to determine the endogenous CPU generation potential of an individual. The parameters obtained by the method quantitatively describe the different mechanisms that influence CPU generation during the complex interplay between coagulation and fibrinolysis, which are in line with the threshold hypothesis.
Keywords: TAFI); Thrombin activatable fibrinolysis inhibitor (proCPU; carboxypeptidase B2; carboxypeptidases; clot lysis time; fibrinolysis; proCPB2.
Similar articles
-
Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?Int J Mol Sci. 2021 Jan 17;22(2):883. doi: 10.3390/ijms22020883. Int J Mol Sci. 2021. PMID: 33477318 Free PMC article. Review.
-
Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.Thromb Haemost. 2003 Feb;89(2):264-71. Thromb Haemost. 2003. PMID: 12574805
-
Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.J Thromb Haemost. 2019 Jun;17(6):878-884. doi: 10.1111/jth.14432. Epub 2019 May 2. J Thromb Haemost. 2019. PMID: 30887647
-
Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.J Thromb Haemost. 2015 Dec;13(12):2227-32. doi: 10.1111/jth.13135. Epub 2015 Nov 12. J Thromb Haemost. 2015. PMID: 26340515
-
Thrombin-activatable fibrinolysis inhibitor.Curr Med Chem. 2004 Sep;11(17):2335-48. doi: 10.2174/0929867043364586. Curr Med Chem. 2004. PMID: 15379716 Review.
Cited by
-
Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.Int J Mol Sci. 2021 Apr 1;22(7):3670. doi: 10.3390/ijms22073670. Int J Mol Sci. 2021. PMID: 33916027 Free PMC article. Review.
-
Changes on proteomic and metabolomic profile in serum of mice induced by chronic exposure to tramadol.Sci Rep. 2021 Jan 14;11(1):1454. doi: 10.1038/s41598-021-81109-7. Sci Rep. 2021. PMID: 33446901 Free PMC article.
-
Unveiling the Influence of Copy Number Variations on Genetic Diversity and Adaptive Evolution in China's Native Pig Breeds via Whole-Genome Resequencing.Int J Mol Sci. 2024 May 27;25(11):5843. doi: 10.3390/ijms25115843. Int J Mol Sci. 2024. PMID: 38892031 Free PMC article.
-
Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?Int J Mol Sci. 2021 Jan 17;22(2):883. doi: 10.3390/ijms22020883. Int J Mol Sci. 2021. PMID: 33477318 Free PMC article. Review.
-
Carboxypeptidase N2 as a Novel Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma.Front Oncol. 2022 May 23;12:843325. doi: 10.3389/fonc.2022.843325. eCollection 2022. Front Oncol. 2022. PMID: 35686102 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous